drugset / Trial / NCT06031480
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
Phase 2
Unknown
55 enrolled
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an multi-center, single arm, exploratory study to evaluate the efficacy and safety of anlitinib combined with TQB2450 in patients with advanced hepatocellular carcinoma （HCC）who failed prior immune checkpoint inhibitor therapies.
Timeline
- Start
- 2023-10-31
- Primary completion
- 2025-10-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |